DSIP
Delta Sleep-Inducing Peptide
Evidence & Status
- Preliminary / Experimental
- Preliminary
At a Glance
A naturally occurring neuropeptide originally isolated from rabbit blood during deep sleep, studied for its potential effects on sleep architecture and the stress response. Human evidence is limited and results from studies have been inconsistent.
Plain English
Researchers study DSIP (Delta Sleep-Inducing Peptide) because it was originally identified as a factor that appeared to promote deep, slow-wave sleep in animal experiments. Scientists have investigated its potential connections to sleep regulation, hypothalamic-pituitary-adrenal axis function, and opioid withdrawal, though results from human studies have been mixed and the compound's precise mechanisms remain incompletely understood. It is one of the more scientifically debated entries in the database, with an interesting discovery history but limited high-quality human evidence.
Overview
DSIP is a synthetic nonapeptide studied in foundational characterization work and in limited experimental human and animal research. The verified literature in this record concerns sleep-related biology, withdrawal symptoms, and pituitary hormone responses; it does not establish generalized sleep normalization, absence of tolerance, broad antioxidant or pain benefits, or current regulatory approval.
Research Summary
DSIP remains preliminary. Verified sources include foundational characterization and limited human reports involving withdrawal symptoms and ACTH/vasopressin responses, but the available evidence is heterogeneous and does not establish generalized sleep normalization, absence of tolerance, broad wellness effects, or current Deltaran regulatory approval.
Research Areas
- Foundational sleep-related biology
- Historical human withdrawal and pituitary hormone-response research
Safety & Risks
Serious Risks
- Limited historical human studies do not establish a general human safety profile or long-term safety.
Legal Status by Region
- United States
- Research only
- United Kingdom
- Current authorization status not established in this record
- Australia
- Current authorization status not established in this record
- Canada
- Current authorization status not established in this record
Citations & Sources
- Characterization of a delta-electroencephalogram (-sleep)-inducing peptide.
Schoenenberger GA, Monnier M · Proceedings of the National Academy of Sciences of the United States of America · 1977
PMID 265572 · DOI 10.1073/pnas.74.3.1282
- The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide.
Monnier M, Dudler L, Gächter R, Maier PF · Experientia · 1977
PMID 862769 · DOI 10.1007/BF01922266
- Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP).
Schoenenberger GA · European Neurology · 1984
PMID 6548966 · DOI 10.1159/000115711
- Successful treatment of withdrawal symptoms with delta sleep-inducing peptide, a neuropeptide with potential agonistic activity on opiate receptors.
Dick P, Grandjean ME, Tissot R · Neuropsychobiology · 1983
PMID 6328354 · DOI 10.1159/000118012
- Reduction of immunoreactive ACTH in plasma following intravenous injection of delta sleep-inducing peptide in man.
Bjartell A, Ekman R, Bergquist S, Widerlöv E · Psychoneuroendocrinology · 1989
PMID 2554357 · DOI 10.1016/0306-4530(89)90004-8
- Different effects of delta-sleep-inducing peptide on arginine-vasopressin and ACTH secretion in normal men.
Chiodera P, Volpi R, Capretti L, Giacalone G, et al. · Hormone Research · 1994
PMID 7698722 · DOI 10.1159/000184207